Adult Hodgkin's Disease and Epstein Barr Virus

描述(申请人提供)：霍奇金氏病的治疗成功 疾病(HD)强调化疗和放射治疗的长期后果 治疗这种疾病的方法。目前的组间试验 反映了无故障存活率的改善，因为它的回报增加了 注意减少幸存者接受治疗的后遗症。.的存在 EB病毒(EBV)在相当大比例的HD肿瘤中提供了 发展病毒特异性肿瘤标记物和 病毒特异性免疫疗法。东方合作肿瘤学小组(ECOG) 西南肿瘤学集团(SWOG)的E2496试验提供了无与伦比的 有机会解决这些问题。通过对这一大群体的评估 是否在活检标本中检测到EBV 确定贫困的风险群体(尤其是45岁以上的患者 几年)应该是可能的。此外，组织的效用的验证 在HD中检测EBV的阵列将使这一技术的发展成为可能 重要且具有成本效益的资源。将进行仔细的分析，以 确定EBV检测研究是在组织阵列中进行还是在血浆中进行 实时聚合酶链式反应的结果与检测研究的结果平行 应用于常规组织切片。同时，确定 血浆中病毒DNA清除率及不同治疗方法的影响 将使用实时聚合酶链式反应(Real-Time-PCR)进行这一清除过程中的方案。这一速度 清除以及病毒DNA在血浆中的持久性将分析为 确定它们是否预测耐药疾病或复发。两国关系 血浆IL-10水平、IL-10启动子基因多态性与EB病毒感染状态的关系 将对肿瘤进行评估。最后，我们试图描述细胞毒性 T细胞对在HD中表达的EBV抗原的反应(在对 其他EBV抗原和来自其他病毒的抗原)，并评估 化疗/放疗对这些反应的影响。这项工作应该为 为未来的病毒抗原靶向治疗奠定基础。

DESCRIPTION (PROVIDED BY APPLICANT): Successes in the treatment of Hodgkin's disease (HD) highlight the long-term consequences of chemotherapy and radiation therapy in the management of this disease. The current inter-group trial reflects the improvement in failure free survival as it pays increasing attention to reducing the late effects of therapy in survivors. The presence of Epstein-Barr virus (EBV) in a significant proportion of HD tumors offers the opportunity to develop the use of virus-specific tumor markers and virus-specific immune therapy. The Eastern Cooperative Oncology Group (ECOG) and Southwestern Oncology Group (SWOG) trial E2496 offers an unparalleled opportunity to address these questions. Through evaluation of this large group of patients, the determination of whether EBV detection in biopsy specimens identifies a poor risk group (particularly in patients over the age of 45 years) should be possible. In addition, the validation of the utility of tissue arrays in the detection of EBV in HD will allow the development of this important and cost-efficient resource. A careful analysis will be performed to determine whether EBV detection studies in tissue arrays or in plasma by real-time PCR yield results parallel to those achieved with detection studies applied to conventional tissue sections. In parallel, the determination of the rate of viral DNA clearance in plasma and the effect of different treatment regimens on this clearance will be performed using real-time PCR. The rate of clearance as well as the persistence of viral DNA in plasma will analyzed to determine if they predict resistant disease or relapse. The relationship between plasma IL-10 levels, IL-10 promoter polymorphisms, and the EBV status of the tumor will be evaluated. Finally, we seek to characterize the cytotoxic T-cell response to EBV antigens expressed in HD (in the context of response to other EBV antigens and antigens from other viruses) and to assess the impact of chemotherapy/radiotherapy on these responses. This work should lay the groundwork for future viral antigen targeted therapies.